Trial Profile
A PHASE 1B/2 STUDY OF IMATINIB IN COMBINATION WITH EVEROLIMUS IN SYNOVIAL SARCOMA (NCI #8603).
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Imatinib (Primary)
- Indications Soft tissue sarcoma
- Focus Adverse reactions; Therapeutic Use
- 31 Jul 2013 Planned End Date changed from 1 Jul 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
- 10 Apr 2013 Planned end date changed from 1 Feb 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.
- 06 Nov 2012 Planned End Date changed from 1 Jun 2014 to 1 Feb 2013, as reported by ClinicalTrials.gov.